Skip to content

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis: An International Comparative Effectiveness Research Project

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05347238
Enrollment
550
Registered
2022-04-26
Start date
2023-02-06
Completion date
2027-03-31
Last updated
2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extreme Prematurity, Late-Onset Neonatal Sepsis, Neonatal Hypotension

Brief summary

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \ 250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \ 35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices. Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS. Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS. Hypothesis: Primary treatment with NE will be associated with a lower mortality Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved: Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

Detailed description

In this study, we will use real world data (RWD; defined as data generated during routine clinical practice) collected by our national Canadian Neonatal Network (CNN), which will be further expanded for this project. The CNN is a well-established patient registry that includes members from 31 hospitals and 17 universities across Canada. The Network maintains a standardized NICU database and provides a unique opportunity for researchers to participate in collaborative projects. We will use the framework of Hypotheses Evaluating Treatment Effectiveness (HETE) research a form of comparative effectiveness research (CER). Patient registries are emerging as a new method for assessment of treatments under the framework of CER. We will evaluate treatment effectiveness of two routinely used primary therapies for hypotension management in very preterm neonates with suspected LOS after standardizing treatment strategies and with a priori hypothesis.

Interventions

DRUGDopamine

Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.

DRUGNorepinephrine

Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

Sponsors

Sunnybrook Health Sciences Centre
CollaboratorOTHER
The Hospital for Sick Children
CollaboratorOTHER
London Health Sciences Centre
CollaboratorOTHER
Windsor Regional Hospital
CollaboratorOTHER
Foothills Medical Centre
CollaboratorOTHER
Health Sciences Centre, Winnipeg, Manitoba
CollaboratorOTHER
St. Boniface Hospital
CollaboratorOTHER
Jewish General Hospital
CollaboratorOTHER
St. Justine's Hospital
CollaboratorOTHER
IWK Health Centre
CollaboratorOTHER
University College Cork
CollaboratorOTHER
Coombe Women and Infants University Hospital
CollaboratorOTHER
Island Health, Victoria, BC
CollaboratorOTHER
Assaf-Harofeh Medical Center
CollaboratorOTHER_GOV
Dayton Children's Hospital
CollaboratorOTHER
Banner University Medical Center
CollaboratorOTHER
Methodist Healthcare
CollaboratorOTHER
Hospital Universitario La Paz
CollaboratorOTHER
McMaster Children's Hospital
CollaboratorOTHER
Children's Hospital of Eastern Ontario
CollaboratorOTHER
BC Women's Hospital & Health Centre
CollaboratorOTHER
Stony Brook University
CollaboratorOTHER
The Children's Hospital at Montefiore
CollaboratorOTHER
Golisano Children's Hospital
CollaboratorUNKNOWN
Mount Sinai Hospital, Canada
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Weeks to 32 Weeks
Healthy volunteers
No

Inclusion criteria

* ≤32 weeks gestational age and \> 48 hours of life * Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)

Exclusion criteria

* Known chromosomal or genetic anomalies * Receiving primary therapy with agents other than Dopamine or Norepinephrine

Design outcomes

Primary

MeasureTime frameDescription
All cause in-hospital mortalityFrom illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birthDeath before discharge

Secondary

MeasureTime frameDescription
Treatment failure rate90 minutes after initial vasopressor initiation (or sooner if secondary dose added or primary agent replaced as per clinical discretion)Need for further dose escalation or use of additional agents (treatment failure = hypotension unresolved after reaching max dose (15mics/kg/min in Dopamine units and 0.15 mics/kg/min in Norepinephrine units)
New diagnosis of severe neurological injuryFrom illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birthGrade III or Grade IV intraventricular hemorrhage or periventricular leukomalacia (yes or no- binary variable)
Episode-related death<14 days from illness onsetEpisode-related death (yes or no- binary variable)
Retinopathy of prematurityFrom illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birthDiagnosis of retinopathy of prematurity - assessed by clinical staff (yes or no - binary variable)
Length of hospital stayFrom admission date to discharge date - assessed up to a maximum of 36 weeks after date of birthLength of entire neonatal intensive care unit stay from admission to discharge
Bronchopulmonary dysplasiaAssessed at 36 weeks PMANeed for oxygen or positive pressure respiratory support at 36 weeks postmenstrual age (PMA) (yes or no- binary variable)

Countries

Canada, Ireland, Israel, Spain, United States

Contacts

Primary ContactAmish Jain, MBBS, MRCPCH, PhD
amish.jain@sinaihealth.ca416-586-4800
Backup ContactLaura Thomas, MSc
laura.thomas@sinaihealth.ca416-586-4800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026